Project Grant R01CA295752
Award Date 1/1/25
Completion Date 12/31/29
Dollars Obligated $527K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- This Project Grant award of $543,221.00 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) is supporting research at the Albert Einstein College of Medicine to better understand the cellular and molecular mechanisms driving lineage plasticity in basal-like breast cancer (BLBC). The key objectives are to: 1) Define the critical de-differentiated cell states involved in BLBC progression and explore strategies to target these cells for cancer...
- This $470,567.00 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) aims to identify molecular features that contribute to response or resistance to PARP-inhibitor therapy in metastatic breast cancer patients without germline BRCA1/2 mutations. The key activities under this 2-year research project involve analyzing pre-treatment tumor DNA and pre- and post-treatment circulating tumor DNA in...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $101,916.00 to the University of Massachusetts Medical School to investigate factors contributing to chemoresistance in BRCA mutant hereditary breast and ovarian cancers. The overall goal is to gain a new understanding of the mechanisms behind chemoresistance in these cancers, which frequently develop resistance to existing chemotherapies and PARP inhibitors. The research aims to...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $170,640 to the Dana-Farber Cancer Institute in Massachusetts to support research into the role of histone cleavage in breast cancer. The project aims to investigate how the histone demethylase KDM4C drives tumor growth in triple-negative breast cancer, a subtype with high treatment resistance and metastasis risk. Key objectives include determining if KDM4C prevents proteolytic...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...
- This federal Project Grant award in the amount of $155,605 was provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, to conduct research on the association between contraception use and ovarian/breast cancers through metabolic profiling. The overarching goal of this 1-year project is to comprehensively quantify changes in metabolites and pathways associated with oral contraception...
- This $292,028 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms by which oncogene amplification leads to genome instability and the development of therapy-resistant cancer clones. The research will be conducted by the Sloan-Kettering Institute for Cancer Research in New York and is scheduled to run from August 1, 2025 to July 31, 2030. Using single-cell genomic sequencing techniques, the project aims...
- The U.S. National Cancer Institute awarded a Project Grant in the amount of $1,056,000.00 to the Sloan-Kettering Institute for Cancer Research, a leading cancer research organization located in New York. The grant, awarded under the federal Cancer Treatment Research program (CFDA 93.395), supports research focused on overcoming resistance to targeted therapies in breast cancer. The key objectives of the research project include elucidating the mechanisms underlying breast cancer plasticity and...
- The National Cancer Institute (NCI) awarded a $487,393 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research in New York, NY, effective December 1, 2024 through November 30, 2029. The grant supports research to determine the role of RAD52, HELQ, and POLQ proteins in backup DNA double-strand break repair pathways, which are critical for the survival of homologous recombination deficient (HRD) cancer cells. The research aims to...
- The National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), awarded a $445,000 project grant to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant, awarded on January 22, 2025, supports DFCI's research on the molecular mechanisms of DNA double-strand break repair by homologous recombination, a critical process for cell survival and cancer prevention. The project aims to define the complex...